| Study | Study design/ Indication | No. of Eyes | Follow-up, months | Criteria for Progression | UV device/ UV energy/ Riboflavin | Outcome | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | Overall | Pre-op K (D) | ΔK (D) | ΔUCVA | ΔBCVA | Δ Refraction (D) |
| Vinciguerra et al, 2012 [31] | Prospective, interventional case series/ Keratoconus | 40 | 24 | Documented keratoconus progression in the previous 3 months | CSO-VEGA X-linker/ Riboflavin 0.1% w dextran 20% | Improved UCVA and BSCVA. Reduced corneal asymmetry and total wavefront aberrations | SIM K Steepest: 51.48 ± 3.4 | From 51.48 ± 3.4 to 50.21 ± 3.2 (P = 0.07) | From 0.79 ± 0.21 to 0.58 ± 0.18 (LogMAR) (P < 0.05) | From 0.39 ± 0.10 to 0.20 ± 0.09 (LogMAR) (P < 0.05) | Mean SE: -1.57 (P = 0.02) |
| Vinciguerra et al, 2010 [27] | Prospective case series/ Post-laser ectasia | 13 | 12 | 1. Δ in myopia/ astigmatism of ≥ 3D/6 months 2. Mean Δ in central and/or pupillary K ≥ 1.50D in 3 consecutive topographies/6 months 3. Total mean CCT ↓ of ≥ 5% in 3 consecutive tomographies/6 months |
Peschke Meditrade/ Riboflavin 0.1% w dextran 20% | Improved BSCVA. Reduced mean SE refraction and mean refractive sphere reduction. | SIM K steepest: 45.93 ± 6.03 | From 45.93 ± 6.03 to 42.49 ± 4.88 (P > 0.05) | From 1.08 ± 0.43 to 0.94 ± 0.46 (LogMAR) (P > 0.05) | From 0.16 ± 0.14 to 0.06 ± 0.08 (LogMAR) (P < 0.05) | SE: From -4.16 ± 2.90 to -3.25 ± 2.05 (P > 0.05) |
| Salgado et al, 2011 [26] | Prospective case series/ Post-laser ectasia | 22 | 12 | Progressive keratectasia after refractive surgery | Peschke Meditrade/ Riboflavin 0.1% w dextran 20% | Improved BCVA, UCVA and max-K. | Max K: 44.12 ± 3.97 | From 44.12 ± 3.97 to 44.43 ± 4.06 (P > 0.05) | From 0.53 ± 0.38 to 0.40 ± 0.27 (LogMAR) (P > 0.05) | From 0.19 ± 0.21 to 0.15 ± 0.14 (LogMAR) (P > 0.05) | SE: From -2.39 ± 2.03 to -2.07 ± 2.18 (LogMAR) (P > 0.05) |
| Ivarsen et al, 2013 [32] | Retrospective follow-up/ Keratoconus | 28 | 22 | 1. ↑ max K ≥ 1.5D/3-6 months 2. ↓ vision and Δ refraction |
IROC UV-X/ Riboflavin 0.1% w dextran 20% | Progression of keratoconus stopped, decreased max K. | Max K: 61.2 ± 3.7 | From 61.2 ± 3.7 to 59.1 ± 3.7 | - | Unchanged | - |
| Richoz et al, 2013 [29] | Retrospective, interventional case series/Post-laser ectasia | 26 | 12-62 (mean follow-up: 25 ± 13) | ↑ Kmax of anterior corneal surface, at 3.0mm from apex of ≥ 1D/12 months | Peschke Meditrade/ Riboflavin 0.1% w dextran 20% | Improved mean CDVA, reduced mean Kmax. Significantly reduced index of surface variance, index of vertical asymmetry, keratoconus index and central keratoconus index | Mean Kmax: 52.8 ± 5 | -1.9 ± 1.9 (P < 0.001) | - | From 0.5 ± 0.3 to 0.2 ± 0.16 (LogMAR) (P < 0.001) | - |